×
About 1,198 results

ALLMedicine™ Factor XIII Center

Research & Reviews  427 results

Hyperfibrinolysis secondary to acquired factor XIII deficiency A case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302284
Medicine Gao L, Li D et. al.

Jul 23rd, 2022 - Hyperfibrinolysis induced by factor XIII deficiency (FXIIID) is extremely rare, and patients with no manifestations of active bleeding can easily and frequently be neglected in clinical practice, leading to a missed diagnosis. Herein, we report a ...

Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review.
https://doi.org/10.1016/j.thromres.2022.07.005
Thrombosis Research; Li Y, Ding B et. al.

Jul 20th, 2022 - Ranging from bleeding to thrombosis, the clinical features of congenital fibrinogen qualitative disorders, including dysfibrinogenemia and hypodysfibrinogenemia, are highly heterogeneous. Although the associations between some specific fibrinogen ...

Factor XIII-A Val34Leu and Tyr204Phe variants influence clot kinetics in a cohort of So...
https://doi.org/10.1016/j.gene.2022.146637
Gene Phasha MN, Soma P et. al.

Jun 8th, 2022 - Factor XIII, a transglutaminase that plays a crucial role in clot formation, consists of subunits A and B. Single nucleotide polymorphisms in Factor XIII-A have been linked to thrombotic risk. In Type 2 Diabetes mellitus (T2DM), a hypercoagulable ...

Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.
https://doi.org/10.1161/ATVBAHA.122.317164
Arteriosclerosis, Thrombosis, and Vascular Biology; Wolberg AS, Sang Y

Jun 3rd, 2022 - As the third most common vascular disease, venous thromboembolism is associated with significant mortality and morbidity. Pathogenesis underlying venous thrombosis is still not fully understood. Accumulating data suggest fibrin network structure a...

Autoimmune Acquired Factor XIII/13 Deficiency after SARS-CoV-2 mRNA Vaccination.
https://doi.org/10.1055/a-1863-7265
Thrombosis and Haemostasis; Nakamura S, Sugasaki M et. al.

Jun 1st, 2022 - Autoimmune Acquired Factor XIII/13 Deficiency after SARS-CoV-2 mRNA Vaccination.|2022|Nakamura S,Sugasaki M,Souri M,Akazawa H,Sogawa M,|

see more →

Drugs  4 results see all →

Clinicaltrials.gov  37 results

Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
https://clinicaltrials.gov/ct2/show/NCT03523624

May 25th, 2022 - Background: The reduction of mortality in acute myocardial infarction (AMI) is achieved by the efficacy of the current therapeutic strategies focused on an early reopening of the culprit coronary artery, by either medical or mechanical reperfusion...

Risk Factors of Neonatal Thrombosis
https://clinicaltrials.gov/ct2/show/NCT05367466

May 10th, 2022 - All newborn patients diagnosed with neonatal thrombosis in our NICU between 2014 and 2019; were included in the study. Patients' data: maternal and neonatal characteristics, consanguinity, need for resuscitation, Apgar scores, diagnoses, need for ...

Embolism in COVID-19 Positive Patients
https://clinicaltrials.gov/ct2/show/NCT04910360

Feb 15th, 2022 - This study has conducted to find the possible links between genetic make up of ICU patients with severe Covid-19 and embolism. 13 polymorphisms and mutations that the investigators targeted are located on Factor II, Factor V, Factor XIII, MTHFR, a...

Perioperative Coagulopathy in Patients Undergoing Cytoreductive Surgery and HIPEC Intraperitoneal Chemotherapy (HIPEC)
https://clinicaltrials.gov/ct2/show/NCT03956836

Mar 9th, 2021 - This prospective observational study aimed at investigating the variations of the values of estándar coagulation test, ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h an...

Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events
https://clinicaltrials.gov/ct2/show/NCT04519398

Aug 19th, 2020 - The study's protocol will cover the following steps: • Collected data from COVID-19 patients at admission will include: Descriptive general demographic data Previous pathologies and thrombosis risk factors Routine biological data (the blood routin...

see more →

News  11 results

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

Whole genome sequencing benefits pediatric ICU patients
https://www.mdedge.com/chestphysician/article/195757/critical-care/whole-genome-sequencing-benefits-pediatric-icu-patients
Jim Kling, MDedge News

Mar 6th, 2019 - SAN DIEGO – In the pediatric intensive care unit (PICU), rapid whole genome sequencing (rWGS) with targeted phenotype analysis often leads to specific changes in patient management, similar to what is seen when rWGS is applied to neonatal ICUs. Th.

Children under 6 with factor XIII deficiency had no major bleeds with recombinant product
https://www.mdedge.com/familymedicine/article/110923/bleeding-disorders/children-under-6-factor-xiii-deficiency-had-no
Hematology News; Neil Osterweil

Jul 28th, 2016 - ORLANDO –A recombinant form of factor XIII was effective at preventing serious bleeding episodes in young children with factor XIII-A subunit deficiency, a rare and serious bleeding disorder. In a small international phase III trial, there were no.

Children under 6 with factor XIII deficiency had no major bleeds with recombinant product
https://www.mdedge.com/pediatrics/article/110923/bleeding-disorders/children-under-6-factor-xiii-deficiency-had-no-major
Neil Osterweil

Jul 28th, 2016 - ORLANDO –A recombinant form of factor XIII was effective at preventing serious bleeding episodes in young children with factor XIII-A subunit deficiency, a rare and serious bleeding disorder. In a small international phase III trial, there were no.

see more →